<DOC>
	<DOCNO>NCT02359292</DOCNO>
	<brief_summary>The study perform evaluate total systemic exposure lung bioavailability CHF 5993 pMDI combination , healthy volunteer subject .</brief_summary>
	<brief_title>Clinical Pharmacology Study Evaluate Total Systemic Exposure Lung Bioavailability CHF 5993 pMDI Combination Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Charcoal</mesh_term>
	<criteria>1 . Subject 's write informed consent obtain prior study related procedure . 2 . Able understand study procedure , risk involve ability train use device correctly . 3 . Male female subject age 18 55 year inclusive . 4 . Body mass index ( BMI ) within range 18 30 kg/m2 inclusive . 5 . Non exsmokers smoke &lt; 5 pack year ( packyears = number cigarette pack per day , time number year ) stop smoke &gt; 1 year prior screen . 6 . Good physical mental status , determine basis medical history general clinical examination , screen randomization . 7 . Lung function measurement within normal limit ( Normal value ( accord GINA 2014 document ) : FEV1/FVC &gt; 0.70 FEV1 &gt; 80 % predict ) . 8 . Male subject : and/or partner must willing use approve method contraception time screen 30 day last dose study . Subjects must donate sperm 30 day last dose study drug . * 9 . Female subject : postmenopausal woman least 12 month natural ( spontaneous ) amenorrhea , woman childbearing potential ( defined woman physiologically capable become pregnant ) , use acceptable method contraception 10 . Surgical sterilization ( i.e . bilateral tubal ligation , hysterectomy female ; vasectomy male ) 11 . Hormonal contraception ( implantable , injectable , patch , oral ) 12 . Doublebarrier method : condom occlusive cap ( diaphragm cervical/vault cap ) 13 . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . 1 . Blood donation ( equal 450 ml ) blood loss , less 8 week inhalation study medication . 2 . Female subject : pregnant lactate woman ( pregnancy define state female conception termination gestation ) confirm positive urine test screen randomization . 3 . Positive HIV1 HIV2 serology . 4 . Positive result Hepatitis serology indicate acute chronic Hepatitis B Hepatitis C. 5 . Unsuitable vein repeat venipuncture . 6 . History alcohol abuse within 12 month prior screen . 7 . History drug abuse within 12 month prior screen ( positive urine drug test perform screen ) . 8 . Subjects positive urine test cotinine . 9 . Clinically relevant abnormal laboratory value suggest unknown disease require clinical investigation . Note : In case abnormal laboratory value , test perform randomization . 10 . Clinically relevant uncontrolled hepatic , gastrointestinal , endocrine , metabolic , neurologic , psychiatric disorder may interfere successful completion protocol . 11 . History glaucoma , symptomatic prostatism urinary retention . 12 . Subjects cardiovascular condition , limited , unstable ischemic heart disease , NYHA Class III/IV leave ventricular failure , acute ischemic heart disease last year prior study screening , history sustain cardiac arrhythmia sustain nonsustained cardiac arrhythmia diagnose last 6 month ( sustain mean last 30 second end external action , lead hemodynamic collapse ; nonsustained mean &gt; 3 beat &lt; 30 second , end spontaneously , asymptomatic ) , impulse conduction high degree block , ICD implant 13 . Abnormal ECG ( i.e . : QRS &gt; 120 msec , PR &gt; 220 msec , HR &lt; 40 bpm , HR &gt; 110 bpm , QTcF &gt; 450 m male QTcF &gt; 470 m female ) screen . Note : In case abnormal ECG , test perform randomization . 14 . Clinically significant abnormal 24hHolter monitoring screening ( necessary Holter evaluation do another day randomization ) . 15 . Abnormal Blood Pressure ( Average Diastolic Blood Pressure &gt; 90 mmHg average Systolic Blood Pressure &gt; 140 mmHg ) screening . Note : In case abnormal blood pressure , measure do randomization . 16 . Participation another clinical trial investigation drug receive less 8 week prior screen . 17 . History hypersensitivity excipients contain formulation use trial . 18 . Subject take drug treatment , include prescribed OTC medicine well vitamin , homeopathic remedy etc , take 14 day screen exception : 1 . Occasional paracetamol ( maximum 2 g per day maximum 10 g per 14 day mild nonexcluding condition ) ; 2 . Hormonal contraceptive ; 3 . Hormonal replacement treatment postmenopausal woman . 19 . Subject take treatment , enzymeinducing enzymeinhibiting drug biologic drug drug know welldefined potential hepatotoxicity ( e.g . isoniazide , nimesulide , ketoconazole ) , take since 3 month screen randomization . 20 . Heavy caffeine drinker ( &gt; 5 caffeinated beverage e.g. , coffee , tea , cola per day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>